source
- Compounders still supply about 20% of US GLP-1 weight-loss market despite FDA crackdown and shortagesA recent Gallup survey shows that while the number of Americans taking GLP-1 weight‑loss drugs has nearly quadrupled over the past two years, roughly one in five are using cheaper, non‑FDA‑approved…
- GSK drops camlipant cough drug after mixed Phase 3 resultsGSK announced it is halting development of camlipant, an experimental chronic cough medicine it acquired in a $2 billion purchase three years ago. The decision follows two Phase 3 trials that show…